Brendan Teehan is COO & VP at ACADIA PHARMACEUTICALS INC (ACAD). They have made 14 open-market trades across 1 company since 2022, most recently 2026-02-11.
CIK 0001891900
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ACAD | SELL | 2024-11-19 | 2024-11-19 | $16.81 | $347K | +2.2% | +3.0% | +21.5% |
| ACAD | SELL | 2024-08-19 | 2024-08-20 | $15.28 | $291K | +5.9% | +4.9% | +8.7% |
| ACAD | SELL | 2024-05-02 | 2024-05-03 | $16.94 | $118K | -11.8% | -10.9% | +10.7% |
| ACAD | SELL · 10b5-1 | 2024-04-08 | 2024-04-09 | $17.87 | $46K | -5.1% | -14.2% | -7.9% |
| ACAD | SELL | 2024-03-27 | 2024-03-27 | $17.90 | $184K | -0.3% | -8.2% | -14.3% |
| ACAD | SELL · 10b5-1 | 2024-02-26 | 2024-02-27 | $24.67 | $15K | -4.9% | -25.0% | -38.8% |
| ACAD | SELL | 2024-01-08 | 2024-01-09 | $29.96 | $22K | -9.5% | -16.3% | -42.0% |
| ACAD | SELL | 2023-11-20 | 2023-11-21 | $22.64 | $225K | +2.6% | +32.6% | +11.6% |
| ACAD | SELL | 2023-05-17 | 2023-05-19 | $22.50 | $669K | -1.7% | -2.0% | +18.8% |
| ACAD | SELL | 2023-05-01 | 2023-05-02 | $21.18 | $12K | +0.0% | +11.4% | +36.3% |
| ACAD | SELL | 2023-04-06 | 2023-04-07 | $18.16 | $32K | +10.4% | +18.8% | +33.6% |
| ACAD | SELL | 2023-02-24 | 2023-02-27 | $18.78 | $9K | +3.3% | -4.4% | +19.8% |
| ACAD | SELL | 2023-01-09 | 2023-01-10 | $17.13 | $9K | +10.9% | +11.1% | +3.4% |
| ACAD | SELL | 2022-05-02 | 2022-05-03 | $18.18 | $10K | -15.5% | -18.7% | -29.3% |
| ACAD | SELL | 2022-02-23 | 2022-02-25 | $23.80 | $11K | +1.3% | -3.2% | -36.3% |
| ACAD | SELL | 2022-01-06 | 2022-01-10 | $23.05 | $12K | -6.5% | +18.5% | +4.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.